Skip to main content

Table 1 Serum tumor markers in bilharzial and non-bilharzial bladder cancer patients compared to normal (unaffected) patients

From: Levels of certain tumor markers as differential factors between bilharzial and non-biharzial bladder cancer among Egyptian patients

Parameters Control Bilharzial bladder
cancer patients
non-bilharzial
bladder cancer
patients
ANOVA
P <
1. XO (μmol uric acid/min/ml)
LSD
0.3 ± 0.05
(2,3)
2.77 ± 0.33
(1,3)
1.58 ± 0.23
(1,2)
P < 0.0001
2. Fructosamine (μmol/L)
LSD
337.88 ± 34.4
(2,3)
1145.27 ± 146.16
(1,3)
742.3 ± 132.44
(1,2)
P < 0.0001
3. hydroxylproline (μg/ml)
LSD
23.35 ± 2.83
(2,3)
78.56 ± 10.48
(1,3)
46.06 ± 4.28
(1,2)
P < 0.0001
4. IgE (IU/ml)
LSD
44.37 ± 1.66
(2,3)
301.49 ± 14.04
(1,3)
269.0 ± 7.66
(1,2)
P < 0.0001
5. TNF- (Pg/ml)
LSD
7.8 ± 0.22
(2,3)
37.7 ± 1.61
(1,3)
24.6 ± 0.84
(1,2)
P < 0.0001
  1. Data are represented as mean ± SD of 10 control and 30 patients (15 patients bilharzial and 15 non-bilharzial)